| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Swiss food conglomerate, Nestlé SA (OTC:NSRGY), announced plans to create products that pair with popular weight-loss medications like Ozempic, Wegovy, and Mounjaro.
As per a Forbes report, this move comes amid concerns about the potential impacts these appetite-suppressing drugs might have on the food industry.
The company’s CEO, Mark Schneider, revealed during an earnings briefing that Nestlé is exploring health aids for the increasing number of individuals utilizing weight-loss treatments. These medications, originally designed to manage Type 2 diabetes, curtail the desire to eat by simulating an appetite-controlling gut hormone.
See Also: Novavax (NVAX) Stock Is Falling Today
Schneider noted that the reduced food intake presents an opportunity for Nestlé to introduce products such as supplements that can support weight loss while ensuring that individuals receive the necessary nutrients. These “companion products” could also help prevent the loss of lean muscle mass and ensure that weight loss is maintained.
In response to concerns about the effect of these weight-loss drugs on the food industry’s revenues, Schneider emphasized that most of Nestlé’s portfolio “will not be affected” as consumers will continue to consume coffee and pet food, two of the company’s major revenue streams. Nonetheless, the company is “carefully” monitoring the situation to ascertain if there will be any impact on demand for its food products.
Read Next: Cannabis Consumers Who Had COVID-19 Experienced Better Outcomes Than Nonusers, New Study Shows
Nestlé. Image Via Shutterstock
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
Posted In: NSRGY
